Andrey Ugolkov

1.9k citations

44 papers · 1.5k indexed · h-index 24

Co-authors: Andrew P. Mazar Thomas V. O’Halloran Vladimir Bilim Yoshihiko Tomita Francis J. Giles Daniel D. Billadeau Vincent L. Cryns Kaori Yuuki
Topics: Wnt/β-catenin signaling in development and cancer (12 papers)Cancer-related gene regulation (9 papers)Pancreatic and Hepatic Oncology Research (5 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Proceedings of the National Academy of Sciences Journal of Clinical Oncology Blood
Partner nations: United States Japan Spain

In The Last Decade

Andrey Ugolkov

43 papers receiving 1.4k citations

Peers

Countries citing papers authored by Andrey Ugolkov

Since Specialization

Citations

This map shows the geographic impact of Andrey Ugolkov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrey Ugolkov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrey Ugolkov more than expected).

Fields of papers citing papers by Andrey Ugolkov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrey Ugolkov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrey Ugolkov. The network helps show where Andrey Ugolkov may publish in the future.

Co-authorship network of co-authors of Andrey Ugolkov

This figure shows the co-authorship network connecting the top 25 collaborators of Andrey Ugolkov. A scholar is included among the top collaborators of Andrey Ugolkov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrey Ugolkov. Andrey Ugolkov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II study of elraglusib (9-ING-41), a GSK-3β inhibitor, in combination with gemcitabine plus nab-paclitaxel in previously untreated metastatic pancreatic cancer 2025 ·ESMO Open ·Devalingam Mahalingam,Anwaar Saeed,Steven Powell,(unknown),Vaibhav Sahai,Andrew L. Coveler,Elizabeth J. Davis,Neeltje Steeghs,Mary F. Mulcahy,Alexander G. Raufi,Ludimila Cavalcante,Andrés Cervantes,Jordan Berlin,(unknown),Andrey Ugolkov,Andrew P. Mazar,(unknown),(unknown),Francis J. Giles,Benedito A. Carneiro	2
2	Correlation of therapy-induced neutropenia with survival in patients with metastatic pancreatic cancer treated with GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study. 2024 ·Journal of Clinical Oncology ·Andrey Ugolkov,(unknown),(unknown),(unknown),(unknown),Suzanne Gagnon,(unknown),Steven D. Reich,Andrew P. Mazar	1
3	Mutational analysis of cfDNA to identify predictive biomarkers in previously untreated patients with metastatic pancreatic cancer receiving the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study. 2024 ·Journal of Clinical Oncology ·Andrey Ugolkov,Taylor M. Weiskittel,(unknown),(unknown),Hu Li,Andrew P. Mazar	1
4	Identification of immune biomarkers in treatment-naive patients with metastatic pancreatic cancer treated with the GSK-3 inhibitor elraglusib (9-ING-41) in combination with gemcitabine/nab-paclitaxel in the 1801 phase 2 study. 2024 ·Journal of Clinical Oncology ·Taylor M. Weiskittel,(unknown),(unknown),(unknown),Benedito A. Carneiro,Hu Li,Andrey Ugolkov,Wafik S. El‐Deiry,Andrew P. Mazar	1
5	Whole-body Imaging of Cell Death Provides a Systemic, Minimally Invasive, Dynamic, and Near-real Time Indicator for Chemotherapeutic Drug Toxicity 2018 ·Clinical Cancer Research ·Steven Johnson,Andrey Ugolkov,Chad R. Haney,Gennadiy Bondarenko,Lin Li,Emily A. Waters,Raymond C. Bergan,(unknown),Thomas V. O’Halloran,Andrew P. Mazar,Ming Zhao	13
6	Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors 2018 ·Molecular Cancer Research ·Isabel Romero‐Calvo,Christopher R. Weber,Mohana Ray,Miguel Brown,Kori Kirby,Rajib Nandi,Tiha M. Long,(unknown),Andrey Ugolkov,Wenan Qiang,Yilin Zhang,Tonya M. Brunetti,Hedy L. Kindler,Jeremy P. Segal,Andrey Rzhetsky,Andrew P. Mazar,Mary M. Buschmann,Ralph Weichselbaum,Kevin K. Roggin,Kevin P. White	86
7	9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma 2018 ·Anti-Cancer Drugs ·Andrey Ugolkov,Gennadiy Bondarenko,Oleksii Dubrovskyi,Ana P. Berbegall,Samuel Navarro,Rosa Noguera,Thomas V. O’Halloran,Mary J.C. Hendrix,Francis J. Giles,Andrew P. Mazar	27
8	Macrogenomic engineering via modulation of the scaling of chromatin packing density 2017 ·Nature Biomedical Engineering ·Luay M. Almassalha,Greta M. Bauer,(unknown),Lusik Cherkezyan,Di Zhang,Alexis M. Kendra,Scott Gladstein,John E. Chandler,(unknown),Brandon-Luke L. Seagle,Andrey Ugolkov,Daniel D. Billadeau,Thomas V. O’Halloran,Andrew P. Mazar,Hemant K. Roy,Igal Szleifer,Shohreh Shahabi,Vadim Backman	32
9	Melanoma Cells Block PEDF Production in Fibroblasts to Induce the Tumor-Promoting Phenotype of Cancer-Associated Fibroblasts 2016 ·Cancer Research ·(unknown),(unknown),Benilde Jiménez,Elena Vinokour,Oleksii Dubrovskyi,Andrey Ugolkov,Andrew P. Mazar,Olga V. Volpert	38
10	GSK-3 inhibition overcomes chemoresistance in human breast cancer 2016 ·Cancer Letters ·Andrey Ugolkov,Irina N. Gaisina,Jin‐San Zhang,Daniel D. Billadeau,Kevin P. White,Alan P. Kozikowski,Sarika Jain,Massimo Cristofanilli,Francis J. Giles,Thomas V. O’Halloran,Vincent L. Cryns,Andrew P. Mazar	63
11	ERK-regulated αB-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo 2015 ·Oncogene ·Dmitry Malin,Elena Strekalova,Vladimír Petrovič,(unknown),Bhawna Sharma,Andrey Ugolkov,WJ Gradishar,Vincent L. Cryns	29
12	Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors 2015 ·Neoplasia ·Gennadiy Bondarenko,Andrey Ugolkov,Stephen Rohan,Piotr Kulesza,Oleksii Dubrovskyi,Demirkan Gursel,(unknown),Thomas V. O’Halloran,Jian Wei,Andrew P. Mazar	65
13	Biodistribution and in vivo toxicity of aptamer-loaded gold nanostars 2014 ·Nanomedicine Nanotechnology Biology and Medicine ·Duncan Hieu M. Dam,Kayla S. B. Culver,Irawati Kandela,(unknown),Kavita Chandra,Hyojin Lee,Christine Mantis,Andrey Ugolkov,Andrew P. Mazar,Teri W. Odom	73
14	Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM) 2014 ·PLoS ONE ·(unknown),Cai Yuan,Ying Wei,Fernando Doñate,Jose Juarez,Graham C. Parry,Liqing Chen,Edward J. Meehan,Richard W. Ahn,Andrey Ugolkov,Oleksii Dubrovskyi,Thomas V. O’Halloran,Mingdong Huang,Andrew P. Mazar	32
15	αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain 2013 ·Clinical Cancer Research ·Dmitry Malin,Elena Strekalova,Vladimír Petrovič,Allison M. Deal,Abraham Al Ahmad,Bárbara Adamo,C. Ryan Miller,Andrey Ugolkov,Chad Livasy,Karen Fritchie,Erika Hamilton,Kimberly Blackwell,Joseph Geradts,(unknown),Lisa A. Carey,Eric V. Shusta,Carey K. Anders,Vincent L. Cryns	81
16	Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells 2012 ·Cell Cycle ·Alexander Yemelyanov,Pankaj Bhalla,Ximing J. Yang,Andrey Ugolkov,(unknown),А. И. Карселадзе,Irina Budunova	42
17	GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC) 2012 ·Biochemical and Biophysical Research Communications ·(unknown),Vladimir Bilim,Andrey Ugolkov,Kaori Yuuki,Sei Naito,Akira Nagaoka,Tomoyuki Kato,Yoshihiko Tomita	38
18	Mutant K-Ras increases GSK-3β gene expression via an ETS-p300 transcriptional complex in pancreatic cancer 2011 ·Oncogene ·(unknown),Alexander Köenig,Andrew M. Harrison,Andrey Ugolkov,Martín E. Fernández-Zapico,Fergus J. Couch,Daniel D. Billadeau	55
19	Glycogen Synthase Kinase-3β: A Prognostic Marker and a Potential Therapeutic Target in Human Bladder Cancer 2010 ·Clinical Cancer Research ·Sei Naito,Vladimir Bilim,Kaori Yuuki,Andrey Ugolkov,Teiichi Motoyama,Akira Nagaoka,Tomoyuki Kato,Yoshihiko Tomita	72
20	Expression analysis of putative stem cell markers in human benign and malignant prostate 2010 ·The Prostate ·Andrey Ugolkov,(unknown),Chunyan Luan,Ximing J. Yang	56

About Andrey Ugolkov

Andrey Ugolkov is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 44 papers that have together received 1.5k indexed citations. Recurring topics across this work include Wnt/β-catenin signaling in development and cancer (12 papers), Cancer-related gene regulation (9 papers) and Pancreatic and Hepatic Oncology Research (5 papers). The work is most often cited by research in Cancer Research (325 citations), Oncology (453 citations) and Molecular Biology (899 citations). Andrey Ugolkov has collaborated with scholars based in United States, Japan and Spain. Frequent co-authors include Andrew P. Mazar, Thomas V. O’Halloran, Vladimir Bilim, Yoshihiko Tomita, Francis J. Giles, Daniel D. Billadeau, Vincent L. Cryns, Kaori Yuuki, Alan P. Kozikowski and Teiichi Motoyama. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact